2023 Q3 Form 10-Q Financial Statement
#000173795323000013 Filed on August 03, 2023
Income Statement
| Concept | 2023 Q3 | 2023 Q2 | 2022 Q2 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Cost Of Revenue | |||
| YoY Change | |||
| Gross Profit | |||
| YoY Change | |||
| Gross Profit Margin | |||
| Selling, General & Admin | $14.73M | $15.21M | $11.40M |
| YoY Change | 15.57% | 33.45% | 29.13% |
| % of Gross Profit | |||
| Research & Development | $49.10M | $40.44M | $29.48M |
| YoY Change | 70.29% | 37.18% | 58.88% |
| % of Gross Profit | |||
| Depreciation & Amortization | $700.0K | $621.0K | $620.0K |
| YoY Change | 13.45% | 0.16% | 19.69% |
| % of Gross Profit | |||
| Operating Expenses | $63.83M | $55.65M | $40.88M |
| YoY Change | 53.52% | 36.14% | 49.29% |
| Operating Profit | -$63.83M | -$55.65M | -$40.88M |
| YoY Change | 53.52% | 36.14% | 49.29% |
| Interest Expense | $4.550M | $4.527M | -$209.0K |
| YoY Change | 709.61% | -2266.03% | -55.15% |
| % of Operating Profit | |||
| Other Income/Expense, Net | $3.586M | $6.294M | -$1.377M |
| YoY Change | -335.46% | -557.08% | -2067.14% |
| Pretax Income | -$60.25M | -$49.35M | -$42.25M |
| YoY Change | 39.77% | 16.81% | 54.71% |
| Income Tax | -$200.0K | $200.0K | $0.00 |
| % Of Pretax Income | |||
| Net Earnings | -$60.00M | -$49.60M | -$42.30M |
| YoY Change | 39.21% | 17.26% | 54.95% |
| Net Earnings / Revenue | |||
| Basic Earnings Per Share | -$0.90 | -$0.75 | -$0.78 |
| Diluted Earnings Per Share | -$0.90 | -$0.75 | -$0.78 |
| COMMON SHARES | |||
| Basic Shares Outstanding | 59.00M shares | 57.78M shares | 54.21M shares |
| Diluted Shares Outstanding | 66.58M shares | 66.37M shares | 54.21M shares |
Balance Sheet
| Concept | 2023 Q3 | 2023 Q2 | 2022 Q2 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $496.8M | $539.1M | $395.1M |
| YoY Change | 33.61% | 36.45% | -13.8% |
| Cash & Equivalents | $76.00M | $106.5M | $112.2M |
| Short-Term Investments | $420.8M | $432.6M | $282.8M |
| Other Short-Term Assets | $8.500M | $7.895M | $4.040M |
| YoY Change | 70.65% | 95.42% | 23.77% |
| Inventory | |||
| Prepaid Expenses | |||
| Receivables | |||
| Other Receivables | |||
| Total Short-Term Assets | $508.2M | $550.0M | $401.9M |
| YoY Change | 33.95% | 36.84% | -13.48% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $8.445M | $7.616M | $8.267M |
| YoY Change | 6.76% | -7.87% | 15.2% |
| Goodwill | |||
| YoY Change | |||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | $1.600M | $1.636M | $1.636M |
| YoY Change | -2.2% | 0.0% | 0.0% |
| Total Long-Term Assets | $54.22M | $53.85M | $57.48M |
| YoY Change | -4.38% | -6.32% | -2.84% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $508.2M | $550.0M | $401.9M |
| Total Long-Term Assets | $54.22M | $53.85M | $57.48M |
| Total Assets | $562.4M | $603.9M | $459.4M |
| YoY Change | 28.96% | 31.44% | -12.28% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $4.365M | $4.883M | $4.482M |
| YoY Change | 9.23% | 8.95% | 88.16% |
| Accrued Expenses | $28.90M | $21.70M | $12.20M |
| YoY Change | 100.35% | 77.86% | 30.33% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | $2.700M | $2.658M | $2.581M |
| YoY Change | 3.85% | 2.98% | 2.99% |
| Total Short-Term Liabilities | $39.83M | $32.24M | $20.31M |
| YoY Change | 69.23% | 58.72% | 34.99% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $52.90M | $52.75M | $24.31M |
| YoY Change | 118.54% | 116.98% | -1.47% |
| Other Long-Term Liabilities | $472.0K | $578.0K | $4.541M |
| YoY Change | -88.97% | -87.27% | -8.78% |
| Total Long-Term Liabilities | $472.0K | $578.0K | $28.85M |
| YoY Change | -98.34% | -98.0% | -2.7% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $39.83M | $32.24M | $20.31M |
| Total Long-Term Liabilities | $472.0K | $578.0K | $28.85M |
| Total Liabilities | $97.23M | $89.86M | $49.17M |
| YoY Change | 86.89% | 82.78% | 9.99% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$595.1M | -$535.0M | -$353.5M |
| YoY Change | 50.05% | 51.34% | 60.33% |
| Common Stock | $59.00K | $57.00K | $49.00K |
| YoY Change | 18.0% | 16.33% | 4.26% |
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $465.2M | $514.0M | $410.3M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $562.4M | $603.9M | $459.4M |
| YoY Change | 28.96% | 31.44% | -12.28% |
Cashflow Statement
| Concept | 2023 Q3 | 2023 Q2 | 2022 Q2 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$60.00M | -$49.60M | -$42.30M |
| YoY Change | 39.21% | 17.26% | 54.95% |
| Depreciation, Depletion And Amortization | $700.0K | $621.0K | $620.0K |
| YoY Change | 13.45% | 0.16% | 19.69% |
| Cash From Operating Activities | -$43.59M | -$48.59M | -$33.46M |
| YoY Change | 31.26% | 45.23% | 82.67% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | $1.750M | $449.0K | $1.068M |
| YoY Change | -541.92% | -57.96% | 267.01% |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | $14.44M | $7.810M | $6.383M |
| YoY Change | 3242.59% | 22.36% | -76.6% |
| Cash From Investing Activities | $12.68M | $7.361M | $5.315M |
| YoY Change | 35122.22% | 38.49% | -80.31% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | $31.04M | ||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | 430.0K | $1.105M | $32.52M |
| YoY Change | -94.21% | -96.6% | 2803.75% |
| NET CHANGE | |||
| Cash From Operating Activities | -43.59M | -$48.59M | -$33.46M |
| Cash From Investing Activities | 12.68M | $7.361M | $5.315M |
| Cash From Financing Activities | 430.0K | $1.105M | $32.52M |
| Net Change In Cash | -30.48M | -$40.11M | $6.297M |
| YoY Change | 18.36% | -736.95% | -37.09% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$43.59M | -$48.59M | -$33.46M |
| Capital Expenditures | $1.750M | $449.0K | $1.068M |
| Free Cash Flow | -$45.34M | -$49.04M | -$34.52M |
| YoY Change | 38.17% | 42.04% | 85.56% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2023Q2 | repl |
Research And Development Incentives Receivable Noncurrent
ResearchAndDevelopmentIncentivesReceivableNoncurrent
|
402000 | usd |
| CY2023Q1 | repl |
Research And Development Incentives Receivable Noncurrent
ResearchAndDevelopmentIncentivesReceivableNoncurrent
|
0 | usd |
| CY2022Q2 | us-gaap |
Operating Expenses
OperatingExpenses
|
40876000 | usd |
| CY2022Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-40876000 | usd |
| CY2022Q2 | repl |
Research And Development Incentives Income
ResearchAndDevelopmentIncentivesIncome
|
851000 | usd |
| CY2022Q2 | us-gaap |
Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
|
343000 | usd |
| CY2022Q2 | us-gaap |
Finance Lease Interest Expense
FinanceLeaseInterestExpense
|
552000 | usd |
| CY2022Q2 | us-gaap |
Interest Expense Debt
InterestExpenseDebt
|
0 | usd |
| CY2022Q2 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-2019000 | usd |
| CY2022Q2 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-1377000 | usd |
| CY2022Q2 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-42253000 | usd |
| CY2022Q2 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | usd |
| CY2022Q2 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-42253000 | usd |
| CY2023Q2 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.75 | |
| CY2022Q2 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.78 | |
| CY2022Q2 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.78 | |
| CY2022Q2 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
54211446 | shares |
| CY2022Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-42253000 | usd |
| CY2022Q2 | us-gaap |
Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
|
1737000 | usd |
| CY2023Q2 | us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
|
0 | usd |
| CY2022Q2 | us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
|
0 | usd |
| CY2022Q2 | us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
|
0 | usd |
| CY2023Q2 | us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
-458000 | usd |
| CY2022Q2 | us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
-244000 | usd |
| CY2023Q2 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-51318000 | usd |
| CY2022Q2 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-40760000 | usd |
| CY2023Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
555292000 | usd |
| CY2023Q2 | us-gaap |
Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
|
-1305000 | usd |
| CY2023Q2 | us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
-458000 | usd |
| CY2023Q2 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
1209000 | usd |
| CY2023Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
8846000 | usd |
| CY2023Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-49555000 | usd |
| CY2023Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
514029000 | usd |
| CY2022Q2 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
31037000 | usd |
| CY2022Q2 | us-gaap |
Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
|
1737000 | usd |
| CY2022Q2 | us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
-244000 | usd |
| CY2023Q2 | us-gaap |
Profit Loss
ProfitLoss
|
-49555000 | usd |
| CY2022Q2 | us-gaap |
Profit Loss
ProfitLoss
|
-42253000 | usd |
| CY2023Q2 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
8846000 | usd |
| CY2022Q2 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
7194000 | usd |
| CY2023Q2 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
621000 | usd |
| CY2022Q2 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
620000 | usd |
| CY2023Q2 | repl |
Net Amortization Of Premiums And Discounts On Short Term Investments
NetAmortizationOfPremiumsAndDiscountsOnShortTermInvestments
|
4091000 | usd |
| CY2022Q2 | repl |
Net Amortization Of Premiums And Discounts On Short Term Investments
NetAmortizationOfPremiumsAndDiscountsOnShortTermInvestments
|
-243000 | usd |
| CY2023Q2 | us-gaap |
Other Noncash Expense
OtherNoncashExpense
|
257000 | usd |
| CY2022Q2 | us-gaap |
Other Noncash Expense
OtherNoncashExpense
|
0 | usd |
| CY2023Q2 | repl |
Unrealized Foreign Currency Transaction Loss Before Tax
UnrealizedForeignCurrencyTransactionLossBeforeTax
|
1374000 | usd |
| CY2022Q2 | repl |
Unrealized Foreign Currency Transaction Loss Before Tax
UnrealizedForeignCurrencyTransactionLossBeforeTax
|
0 | usd |
| CY2023Q2 | repl |
Increase Decrease In Research And Development Incentives Receivable
IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable
|
393000 | usd |
| CY2022Q2 | repl |
Increase Decrease In Research And Development Incentives Receivable
IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable
|
850000 | usd |
| CY2023Q2 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
1577000 | usd |
| CY2022Q2 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-1158000 | usd |
| CY2023Q2 | repl |
Increase Decrease Operating Lease Right Of Use Asset
IncreaseDecreaseOperatingLeaseRightOfUseAsset
|
-148000 | usd |
| CY2022Q2 | repl |
Increase Decrease Operating Lease Right Of Use Asset
IncreaseDecreaseOperatingLeaseRightOfUseAsset
|
-126000 | usd |
| CY2023Q2 | repl |
Increase Decrease Finance Lease Right Of Use Asset
IncreaseDecreaseFinanceLeaseRightOfUseAsset
|
-607000 | usd |
| CY2022Q2 | repl |
Increase Decrease Finance Lease Right Of Use Asset
IncreaseDecreaseFinanceLeaseRightOfUseAsset
|
-607000 | usd |
| CY2023Q2 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-816000 | usd |
| CY2022Q2 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
895000 | usd |
| CY2023Q2 | repl |
Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
|
-1215000 | usd |
| CY2022Q2 | repl |
Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
|
-1067000 | usd |
| CY2023Q2 | us-gaap |
Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
|
-153000 | usd |
| CY2022Q2 | us-gaap |
Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
|
-128000 | usd |
| CY2023Q2 | us-gaap |
Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
|
107000 | usd |
| CY2022Q2 | us-gaap |
Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
|
0 | usd |
| CY2023Q2 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-48588000 | usd |
| CY2022Q2 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-33455000 | usd |
| CY2023Q2 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
449000 | usd |
| CY2022Q2 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
1068000 | usd |
| CY2023Q2 | us-gaap |
Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
|
169330000 | usd |
| CY2022Q2 | us-gaap |
Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
|
60617000 | usd |
| CY2023Q2 | us-gaap |
Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
|
177140000 | usd |
| CY2022Q2 | us-gaap |
Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
|
67000000 | usd |
| CY2023Q2 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
7361000 | usd |
| CY2022Q2 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
5315000 | usd |
| CY2023Q2 | repl |
Proceeds From Issuance Of Common Stock Through Atm Sales Net
ProceedsFromIssuanceOfCommonStockThroughATMSalesNet
|
0 | usd |
| CY2022Q2 | repl |
Proceeds From Issuance Of Common Stock Through Atm Sales Net
ProceedsFromIssuanceOfCommonStockThroughATMSalesNet
|
31037000 | usd |
| CY2023Q2 | us-gaap |
Finance Lease Principal Payments
FinanceLeasePrincipalPayments
|
104000 | usd |
| CY2022Q2 | us-gaap |
Finance Lease Principal Payments
FinanceLeasePrincipalPayments
|
77000 | usd |
| CY2023Q2 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
1209000 | usd |
| CY2022Q2 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
1562000 | usd |
| CY2023Q2 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
1105000 | usd |
| CY2022Q2 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
32522000 | usd |
| CY2023Q2 | us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
13000 | usd |
| CY2022Q2 | us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
1915000 | usd |
| CY2023Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-40109000 | usd |
| CY2022Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
6297000 | usd |
| CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
148226000 | usd |
| CY2022Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
107584000 | usd |
| CY2023Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
108117000 | usd |
| CY2022Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
113881000 | usd |
| CY2023Q2 | us-gaap |
Interest Paid Net
InterestPaidNet
|
653000 | usd |
| CY2022Q2 | us-gaap |
Interest Paid Net
InterestPaidNet
|
0 | usd |
| CY2023Q2 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
412000 | usd |
| CY2022Q2 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
318000 | usd |
| CY2023Q2 | us-gaap |
Nature Of Operations
NatureOfOperations
|
Nature of the business<div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Replimune Group, Inc. (the “Company”) is a clinical-stage biotechnology company committed to applying its leading expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through its novel tumor-directed oncolytic immunotherapies. The Company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Replimune Group, Inc., whose predecessor was founded in 2015, is the parent company of its wholly owned, direct and indirect subsidiaries: Replimune Limited (“Replimune UK”); Replimune, Inc. (“Replimune US”); Replimune Securities Corporation; and Replimune (Ireland) Limited.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, third-party intellectual property, compliance with government regulations and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance and reporting capabilities. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of presentation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. The Company has incurred recurring losses since its inception, including net losses of $49.6 million and $42.3 million for the three months ended June 30, 2023 and 2022, respectively. In addition, as of June 30, 2023, the Company had an accumulated deficit of $535.0 million. The Company expects to continue to generate operating losses for the foreseeable future. As of the issuance date of these consolidated financial statements, the Company expects that its cash and cash equivalents and short-term investments will be sufficient to fund its operating expenses and capital expenditure requirements through at least 12 months from the issuance of these consolidated financial statements.</span></div> | |
| CY2023Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-49600000 | usd |
| CY2022Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-42300000 | usd |
| CY2023Q2 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-535000000 | usd |
| CY2023Q2 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
7863000 | usd |
| CY2023Q1 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
7242000 | usd |
| CY2023Q2 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
7616000 | usd |
| CY2023Q2 | us-gaap |
Use Of Estimates
UseOfEstimates
|
The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual for research and development expenses and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. | |
| CY2023Q2 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
15479000 | usd |
| CY2023Q1 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
14721000 | usd |
| CY2023Q1 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
7479000 | usd |
| CY2023Q2 | us-gaap |
Depreciation
Depreciation
|
621000 | usd |
| CY2022Q2 | us-gaap |
Depreciation
Depreciation
|
620000 | usd |
| CY2023Q2 | repl |
Accrued Research And Development Costs
AccruedResearchAndDevelopmentCosts
|
14959000 | usd |
| CY2023Q1 | repl |
Accrued Research And Development Costs
AccruedResearchAndDevelopmentCosts
|
11261000 | usd |
| CY2023Q2 | us-gaap |
Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
|
5204000 | usd |
| CY2023Q1 | us-gaap |
Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
|
9909000 | usd |
| CY2023Q2 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
402000 | usd |
| CY2023Q1 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
540000 | usd |
| CY2023Q2 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
2997000 | usd |
| CY2023Q1 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
2994000 | usd |
| CY2023Q2 | us-gaap |
Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
|
23562000 | usd |
| CY2023Q1 | us-gaap |
Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
|
24704000 | usd |
| CY2023Q2 | repl |
Long Term Debt Instrument Covenant Requirement Unrestricted Cash Percentage Of Obligations
LongTermDebtInstrumentCovenantRequirementUnrestrictedCashPercentageOfObligations
|
0.35 | |
| CY2022Q4 | repl |
Long Term Debt End Of Term Charge
LongTermDebtEndOfTermCharge
|
1500000 | usd |
| CY2023Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
150000000 | shares |
| CY2023Q2 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
150000000 | shares |
| CY2023Q2 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2023Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2023Q2 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | shares |
| CY2023Q2 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2023Q2 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2023 | us-gaap |
Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
|
340000 | shares |
| CY2023 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
6700000 | usd |
| CY2023 | us-gaap |
Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
|
300000 | usd |
| CY2019Q4 | us-gaap |
Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
|
4516561 | shares |
| CY2019Q4 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
85600000 | usd |
| CY2020Q2 | us-gaap |
Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
|
3478261 | shares |
| CY2020Q2 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
107800000 | usd |
| CY2020Q4 | us-gaap |
Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
|
5625000000 | shares |
| CY2020Q4 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
270000000 | usd |
| CY2022Q4 | us-gaap |
Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
|
6810658000 | shares |
| CY2022Q4 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
242600000 | usd |
| CY2023Q2 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
8846000 | usd |
| CY2022Q2 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
7194000 | usd |
| CY2023Q2 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
8846000 | usd |
| CY2022Q2 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
7194000 | usd |
| CY2017Q3 | repl |
Conversion Of Stock Ratio
ConversionOfStockRatio
|
1 | |
| CY2018Q3 | us-gaap |
Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
|
7561583 | shares |
| CY2021Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
125000000 | shares |
| CY2022Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
82500000 | shares |
| CY2023Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
7454828 | shares |
| CY2023Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
17.24 | |
| CY2023 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P6Y10M17D | |
| CY2023Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
31244000 | usd |
| CY2023Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
1802406 | shares |
| CY2023Q2 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
17.94 | |
| CY2023Q2 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
96146 | shares |
| CY2023Q2 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
12.58 | |
| CY2023Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
93783 | shares |
| CY2023Q2 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
24.80 | |
| CY2023Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
9067305 | shares |
| CY2023Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
17.35 | |
| CY2023Q2 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P6Y11M8D | |
| CY2023Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
69685000 | usd |
| CY2023Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
5254968 | shares |
| CY2023Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
15.03 | |
| CY2023Q2 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P5Y9M7D | |
| CY2023Q2 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
|
52342000 | usd |
| CY2023Q2 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
|
9067305 | shares |
| CY2023Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
|
17.35 | |
| CY2023Q2 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
|
P6Y11M8D | |
| CY2023Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
|
69685000 | usd |
| CY2023Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
12.09 | |
| CY2022Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
12.15 | |
| CY2023Q2 | repl |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue
|
500000 | usd |
| CY2023Q2 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-49555000 | usd |
| CY2022Q2 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-42253000 | usd |
| CY2023Q2 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
66367702 | shares |
| CY2023Q2 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
66367702 | shares |
| CY2022Q2 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
54211446 | shares |
| CY2022Q2 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
54211446 | shares |
| CY2023Q2 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.75 | |
| CY2023Q2 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.75 | |
| CY2022Q2 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.78 | |
| CY2022Q2 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.78 | |
| CY2018Q3 | us-gaap |
Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
|
7561583 | shares |
| CY2023Q2 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
11634064 | shares |
| CY2022Q2 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
9265026 | shares |
| CY2023Q2 | us-gaap |
Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
|
607000 | usd |
| CY2022Q2 | us-gaap |
Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
|
607000 | usd |
| CY2023Q2 | us-gaap |
Finance Lease Interest Expense
FinanceLeaseInterestExpense
|
544000 | usd |
| CY2022Q2 | us-gaap |
Finance Lease Interest Expense
FinanceLeaseInterestExpense
|
552000 | usd |
| CY2023Q2 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
280000 | usd |
| CY2022Q2 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
259000 | usd |
| CY2023Q2 | us-gaap |
Lease Cost
LeaseCost
|
1431000 | usd |
| CY2022Q2 | us-gaap |
Lease Cost
LeaseCost
|
1418000 | usd |
| CY2023Q2 | us-gaap |
Finance Lease Interest Expense
FinanceLeaseInterestExpense
|
544000 | usd |
| CY2022Q2 | us-gaap |
Finance Lease Interest Expense
FinanceLeaseInterestExpense
|
552000 | usd |
| CY2023Q2 | us-gaap |
Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
|
848000 | usd |
| CY2023Q2 | us-gaap |
Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
|
1990000 | usd |
| CY2023Q2 | repl |
Operating And Finance Lease Liability Payments Remainder Of Fiscal Year
OperatingAndFinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
|
2838000 | usd |
| CY2023Q2 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
1170000 | usd |
| CY2023Q2 | us-gaap |
Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
|
2718000 | usd |
| CY2023Q2 | repl |
Operating And Finance Lease Liability Payments Due Next Twelve Months
OperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths
|
3888000 | usd |
| CY2023Q2 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
1179000 | usd |
| CY2023Q2 | us-gaap |
Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
|
2799000 | usd |
| CY2023Q2 | repl |
Operating And Finance Lease Liability Payments Due Year Two
OperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo
|
3978000 | usd |
| CY2023Q2 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
1144000 | usd |
| CY2023Q2 | us-gaap |
Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
|
2883000 | usd |
| CY2023Q2 | repl |
Operating And Finance Lease Liability Payments Due Year Three
OperatingAndFinanceLeaseLiabilityPaymentsDueYearThree
|
4027000 | usd |
| CY2023Q2 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
|
1093000 | usd |
| CY2023Q2 | us-gaap |
Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
|
2969000 | usd |
| CY2023Q2 | repl |
Operating Finance Lease Liability Payments Due Year Four
OperatingFinanceLeaseLiabilityPaymentsDueYearFour
|
4062000 | usd |
| CY2023Q2 | repl |
Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
|
1943000 | usd |
| CY2023Q2 | repl |
Finance Lease Liability To Be Paid After Year Four
FinanceLeaseLiabilityToBePaidAfterYearFour
|
35054000 | usd |
| CY2023Q2 | repl |
Operating And Finance Lease Liability Payments Due After Year Four
OperatingAndFinanceLeaseLiabilityPaymentsDueAfterYearFour
|
36997000 | usd |
| CY2023Q2 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
7377000 | usd |
| CY2023Q2 | us-gaap |
Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
|
48413000 | usd |
| CY2023Q2 | repl |
Operating And Finance Lease Liability Payments Due
OperatingAndFinanceLeaseLiabilityPaymentsDue
|
55790000 | usd |
| CY2023Q2 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
1943000 | usd |
| CY2023Q2 | us-gaap |
Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
|
21913000 | usd |
| CY2023Q2 | repl |
Operating And Finance Lease Liability Undiscounted Excess Amount
OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount
|
23856000 | usd |
| CY2023Q2 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
5434000 | usd |
| CY2023Q2 | us-gaap |
Finance Lease Liability
FinanceLeaseLiability
|
26500000 | usd |
| CY2023Q2 | repl |
Operating And Finance Lease Liability
OperatingAndFinanceLeaseLiability
|
31934000 | usd |
| CY2023Q2 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
5137000 | usd |
| CY2023Q1 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
5208000 | usd |
| CY2023Q2 | us-gaap |
Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
|
39058000 | usd |
| CY2023Q1 | us-gaap |
Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
|
39665000 | usd |
| CY2023Q2 | repl |
Lease Right Of Use Asset
LeaseRightOfUseAsset
|
44195000 | usd |
| CY2023Q1 | repl |
Lease Right Of Use Asset
LeaseRightOfUseAsset
|
44873000 | usd |
| CY2023Q2 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
1139000 | usd |
| CY2023Q1 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
1118000 | usd |
| CY2023Q2 | us-gaap |
Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
|
2658000 | usd |
| CY2023Q1 | us-gaap |
Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
|
2639000 | usd |
| CY2023Q2 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
4295000 | usd |
| CY2023Q1 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
4389000 | usd |
| CY2023Q2 | us-gaap |
Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
|
23842000 | usd |
| CY2023Q1 | us-gaap |
Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
|
23965000 | usd |
| CY2023Q2 | repl |
Lease Liability
LeaseLiability
|
31934000 | usd |
| CY2023Q1 | repl |
Lease Liability
LeaseLiability
|
32111000 | usd |
| CY2023Q2 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
263000 | usd |
| CY2022Q2 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
261000 | usd |
| CY2023Q2 | us-gaap |
Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
|
544000 | usd |
| CY2022Q2 | us-gaap |
Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
|
552000 | usd |
| CY2023Q2 | us-gaap |
Finance Lease Principal Payments
FinanceLeasePrincipalPayments
|
104000 | usd |
| CY2022Q2 | us-gaap |
Finance Lease Principal Payments
FinanceLeasePrincipalPayments
|
77000 | usd |
| CY2023Q2 | us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
0 | usd |
| CY2022Q2 | us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
0 | usd |
| CY2023Q2 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P6Y3M18D | |
| CY2022Q2 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P7Y7M6D | |
| CY2023Q2 | us-gaap |
Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
|
P16Y1M6D | |
| CY2022Q2 | us-gaap |
Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
|
P17Y3M18D | |
| CY2023Q2 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.103 | |
| CY2022Q2 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.100 | |
| CY2023Q2 | us-gaap |
Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
|
0.083 | |
| CY2022Q2 | us-gaap |
Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
|
0.083 | |
| CY2023Q2 | us-gaap |
Purchase Commitment Remaining Minimum Amount Committed
PurchaseCommitmentRemainingMinimumAmountCommitted
|
900000 | usd |
| CY2023Q1 | us-gaap |
Purchase Commitment Remaining Minimum Amount Committed
PurchaseCommitmentRemainingMinimumAmountCommitted
|
1000000 | usd |
| CY2023Q2 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
200000 | usd |
| CY2023Q2 | repl |
Number Of Operating Geographic Regions
NumberOfOperatingGeographicRegions
|
2 | region |
| CY2023Q2 | us-gaap |
Noncurrent Assets
NoncurrentAssets
|
7616000 | usd |
| CY2023Q1 | us-gaap |
Noncurrent Assets
NoncurrentAssets
|
7479000 | usd |
